Abstract:Currently, the curative effects of polypeptide drugs are often restricted due to the short in vivo duration of action. In this study, we fused a series of heptapeptide tags with different length fatty chains to the N-terminus of mutated glucagon-like peptide-1 (GLP-1) using an intermediate sequence comprising a flexible linker (GGGGS)2 and thrombin (TBN)-cleavable site (FNPR), to develop promising prolonged GLP-1 receptor (GLP-1R) agonists. As a result, twenty-one fusion peptides, termed PES01-PES21, were designed and prepared. Surface plasmon resonance (SPR) measurements and plasma stability tests showed that PES14 exert better albumin binding affinity and in vitro plasma stability compared with the other ones. Preclinical assay in db/db mice proved that PES14 exert the hypoglycemic efficacies in a dose-dependent model within the range of 10-90 nmol kg-1. Furtherly, an enhanced glucose-lowering effect and significantly prolonged hypoglycemic duration of PES14 were exhibited in multiple oral glucose tolerance tests (OGTTs) and hypoglycemic duration test, compared with Liraglutide and Semaglutide, respectively. Moreover, the in vivo t 1/2 of intact PES14 and released GLP-1 were approximately 95.1 h and 110.5 h in rhesus monkeys after a single subcutaneous injection of 90 nmol kg-1, respectively. Furthermore, long-term treatment with PES14 in db/db mice for 8 weeks obtained beneficial efficacies on body weight gain, food intake, fat% and hemoglobin A1c (HbA1c) reduction compared with the control and superior to those of Semaglutide treatment. Meanwhile, chronic treatment of PES14 also exhibited proper insulin immunoreactivity and effectively enhanced the improvement on hepatocyte damage. All these results suggested that PES14 has the potential to be developed as a once-weekly anti-diabetic drug.

Microwave-assisted Solid Phase Synthesis, PEGylation, and Biological Activity Studies of Glucagon-Like Peptide-1(7–36) Amide

Synthesis And Biological Activity Studies Of Glucagon-Like Peptide-1 Analogues

Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide-1 analogues.

Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues.

Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1

The Study on PEGylation and Biological Activity of Insulinotropic Analogues

Mpegylation of Insulin and Characterization of Its Activity

Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects

Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1

Solid Phase Synthesis of Glucagon-Like Peptide-1 Analogues under Microwave Irradiation and Their Hypoglycemic Activities

Synthesis and pharmaceutical characterization of site specific mycophenolic acid-modified Xenopus glucagon-like peptide-1 analogs

Nanoparticles induced by embedding self-assembling cassette into glucagon-like peptide 1 for improving in vivo stability.

Modified Condition Optimization of the Pegylation of Glucagon-like Peptide-

Novel Fatty Acid Chain Modified GLP-1 Derivatives with Prolonged in Vivo Glucose-Lowering Ability and Balanced Glucoregulatory Activity.

A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.

Development of a C‐Terminal Site‐Specific PEGylated Analog of GLP‐1 with Improved Anti‐Diabetic Effects in Diabetic Mice

Novel Fatty Chain-Modified Glucagon-Like Peptide-1 Conjugates with Enhanced Stability and Prolonged in Vivo Activity.

Α/sulfono-Γ-aapeptide Hybrid Analogues of Glucagon with Enhanced Stability and Prolonged in Vivo Activity

A New GLP-1 Analogue with Prolonged Glucose-Lowering Activity in Vivo Via Backbone-Based Modification at the N-terminus

Molecular design of peptide therapeutics via N-terminal modification

Identification of the effect of N-glycan modification and its sialylation on proteolytic stability and glucose-stabilizing activity of glucagon-like peptide 1 by site-directed enzymatic glycosylation